Don't miss our LEUKEMIA 360 partnership event, registration is limited! Access the website

  • ATMP development
  • ALL
  • AML
  • Cell therapy
  • Immunotherapy
  • CAR-T cells
  • Preclinical research (TRL 4-5)
  • Clinical research (TRL 6-8)

Preclinical and clinical evaluation of the efficacy and toxicity (pre-regulatory) of CAR-T cell therapy treatments.

Combining expertise from the preclinical to the clinical stage, to assess the potential of the therapeutic solution.


Description

Scope of research activities

Preclinical and clinical research for the development of new CAR-T cell therapies.

  • Preclinical (in vivo) evaluation studies of CAR-T cells (new CARs, new targets, new CAR+ cells)
  • Ancillary studies: identification of predictive markers of CAR-T cell efficacy/toxicity
  • Clinical protocol: immunomonitoring of patients treated with CAR-T cells

Conduct of studies

  • Assessment and definition of project requirements
  • Study design and project implementation
  • Analysis and communication of results

Research infrastructure

Experimental and analysis platforms:

  • Spectral cytometry (Aurora, Cytec)
  • Imaging (IVIS, Incucyte)
  • Animal facilities (immunodeficient NGS mice

Specifications

The platform

Assessing the anti-tumor potential of CAR-T cell therapies for hematological malignancies.

The studies 

Mouse model to assess CAR-T cell efficacy and toxicity: 

  • Immunodeficient NGS mice 
  • i.v., i.p. or orthotopic injection of human tumor lines expressing the CAR target

In vitro model for evaluating CAR-T cell efficacy:

  • Cytotoxicity tests (bioluminescence, Incucyte)
  • 3D spheroids

Immunomonitoring of patients treated with CAR-T cells:

  • Multiparametric cytometry
  • Cytokine assay

Examples of partnerships

To test in humans the relevance of observations made in preclinical models of CAR-T cells.

Partner: Institut Pasteur /Inserm 1223 (Dr. Philippe Bousso, Unité "Dynamiques des Réponses Immunes ») 

 


Terms

Contact us